Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

被引：347

作者：

Kirn, D ^{[1
]}

Martuza, RL

Zwiebel, J

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Viral & Genet Therapy Programme, Sch Med, London, England

[2] Hammersmith Hosp, Imperial Canc Res Fund, London, England

[3] Harvard Univ, Sch Med, Boston, MA USA

[4] Massachusetts Gen Hosp, Boston, MA 02114 USA

[5] NCI, Div Canc Treatment, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA

来源：

NATURE MEDICINE | 2001年 / 7卷 / 07期

关键词：

D O I：

10.1038/89901

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

In the search for novel cancer therapies that can be used in conjunction with existing treatments, one promising area of research is the use of viral vectors and whole viruses. This review describes the underlying biological principles and current status of the field, outlines approaches for improving clinical effectiveness and discusses the unique safety and regulatory issues surrounding viral therapies.

引用

收藏

页码：781 / 787

页数：7

相关论文

共 79 条

[21] A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma [J].

Hallenbeck, PL ;

Chang, YN ;

Hay, C ;

Golightly, D ;

Stewart, D ;

Lin, J ;

Phipps, S ;

Chiang, YL .

HUMAN GENE THERAPY, 1999, 10 (10) :1721-1733

[22] p53-independent and -dependent requirements for E1B-55K in adenovirus type 5 replication [J].

Harada, JN ;

Berk, AJ .

JOURNAL OF VIROLOGY, 1999, 73 (07) :5333-5344

[23]

HECHT R, 2000, P AN M AM SOC CLIN, V19, P1039

[24] An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy [J].

Heise, C ;

Hermiston, T ;

Johnson, L ;

Brooks, G ;

Sampson-Johannes, A ;

Williams, A ;

Hawkins, L ;

Kirn, D .

NATURE MEDICINE, 2000, 6 (10) :1134-1139

[25] ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents [J].

Heise, C ;

SampsonJohannes, A ;

Williams, A ;

McCormick, F ;

VonHoff, DD ;

Kirn, DH .

NATURE MEDICINE, 1997, 3 (06) :639-645

[26]

Heise C, 2000, CLIN CANCER RES, V6, P4908

[27] Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: Intratumoral spread and distribution effects [J].

Heise, CC ;

Williams, A ;

Olesch, J ;

Kirn, DH .

CANCER GENE THERAPY, 1999, 6 (06) :499-504

[28]

Heise CC, 1999, CANCER RES, V59, P2623

[29] Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer [J].

Hermiston, T .

JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (09) :1169-1172

[30] Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector [J].

Herrlinger, U ;

Kramm, CM ;

Aboody-Guterman, KS ;

Silver, JS ;

Ikeda, K ;

Johnston, KM ;

Pechan, PA ;

Barth, RF ;

Finkelstein, D ;

Chiocca, EA ;

Louis, DN ;

Breakefield, XO .

GENE THERAPY, 1998, 5 (06) :809-819

← 1 2 3 4 5 6 7 8 →